Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
Completed · Not applicable
Conditions studied: Metastatic Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma
In brief
This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.
Key facts
- Study ID
- NCT05078775
- Run by
- Faeth Therapeutics
- People needed
- 39
- Starts
- 2021-12-21
- Expected to finish
- 2025-07-10
- Last updated by the study team
- 2025-07-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Arizona Cancer Center — Tucson, Arizona, United States
- Oncology Physicians Network — Glendale, California, United States
- Cedars-Sinai — Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
- Florida Cancer Specialists — Fort Myers, Florida, United States
- Atlantic Health — Morristown, New Jersey, United States
- xCures - Virtual Site — Raleigh, North Carolina, United States
- Sarah Cannon — Nashville, Tennessee, United States
- Baptist Hospitals of Southeast Texas — Beaumont, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.